These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15720419)

  • 1. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
    Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
    Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
    Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of clinical and immunological parameters in diffuse large B-cell lymphomas.
    Tsartsidze E; Betaneli M
    Georgian Med News; 2006 Apr; (133):96-9. PubMed ID: 16705242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
    Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
    Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
    Xu Y; McKenna RW; Molberg KH; Kroft SH
    Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of prognostic factors in 74 cases of diffuse large B-cell lymphoma].
    Wang J; Ke XY; Zhao LZ; Li M; Jing HM; Wang JJ; Zhao W; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):667-70. PubMed ID: 18399171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.